Physician

David Young, DO

According to 2025 Medicare claims, David Young, DO (NPI: 1285954321) practices pulmonary disease in the Reading, PA market, with the plurality of this provider's patient population coming from Berks, PA. This provider's primary affiliated billing organization is RESPIRATORY SPECIALISTS LTD (NPI: 1801816152; TIN: 23-2197079) and primary practice location at 19610-3333.

Young's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 677 traditional Medicare patients, billed 3,972 HCPCS/CPT codes, and received $224,380 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 1,544 prescription claims across 280 beneficiaries totaling $1,053,517 in drug costs, led by Ofev (Nintedanib Esylate). DME data shows 1,532 claims. Open Payments data shows 46 records totaling $1,044. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $44,562 to $224,380. Similarly, Part D prescription costs have moved sharply higher in recent years, from $20,474 to $1,053,517. For DME billing, reported payments rose steadily, from $3,223 to $61,718.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	192	552	$44,562
2017	584	1,716	$134,182
2018	643	1,963	$134,670
2019	655	2,135	$143,310
2020	644	1,984	$154,490
2021	635	2,754	$166,287
2022	614	3,495	$184,907
2023	739	3,902	$225,489
2024	677	3,972	$224,380

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	N/R	N/R	N/R
2016	42	108	$20,474
2017	78	309	$76,770
2018	122	442	$124,145
2019	155	726	$218,524
2020	189	967	$430,302
2021	189	1,264	$623,621
2022	216	1,400	$594,357
2023	240	1,659	$835,728
2024	280	1,544	$1,053,517

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	64	$2,054
2018	38	308	$17,848
2019	85	498	$27,087
2020	294	935	$100,840
2021	320	998	$111,130
2022	330	1,033	$79,149
2023	457	1,400	$110,383
2024	548	1,532	$90,182

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	116	116	$118
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	175	245	$84
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	233	526	$82
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	155	194	$53
96160	Administration and interpretation of patient-focused health risk assessment	229	473	$2

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ofev	Nintedanib Esylate	19	570	$245,880
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	195	10,770	$223,126
Esbriet	Pirfenidone	11	330	$114,062
Breo Ellipta	Fluticasone/Vilanterol	130	6,390	$80,901
Stiolto Respimat	Tiotropium Br/Olodaterol Hcl	64	3,360	$50,589

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7677	Revefenacin inhalation solution, fda-approved final product, non-compounded, administered through dme, 1 microgram	N	N/R	28	$21,223
E0466	Home ventilator, any type, used with non-invasive interface, (e.g., mask, chest shell)	Y	N/R	12	$12,181
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	11	92	$7,156
A7030	Full face mask used with positive airway pressure device, each	N	47	78	$6,113
J7606	Formoterol fumarate, inhalation solution, fda approved final product, non-compounded, administered through dme, unit dose form, 20 micrograms	N	N/R	32	$6,052

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	46	$1,044	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for David Young, DO?

Tedicare shows public-source Medicare data for David Young, DO (NPI 1285954321), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does David Young, DO have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to David Young, DO?

David Young, DO is linked to RESPIRATORY SPECIALISTS LTD (billing NPI 1801816152) in the available physician profile data.

Does David Young, DO have Open Payments data?

David Young, DO has 46 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.